Overview
TEVA market data
Price History
TEVA price chart · 1M
- O
- 37.86
- H
- 38.36
- L
- 37.54
- C
- 37.77
- Vol
- 191,978.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $37.86
- Previous Close
- $37.96
- Day High
- $38.36
- Day Low
- $37.54
- 52 Week High
- $38.36
- 52 Week Low
- $29.63
- 7 Day Return
- +2.65%
- 30 Day Return
- +19.32%
- 90 Day Return
- +7.13%
- 1 Year Return
- +6.68%
- Daily Notional Volume
- $7.3M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 60.73 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.21 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.46 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 4.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5,990.00 – $11,440.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $128.4B · P/B 4.90 · P/S 2.49.
Company News
Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobenewswire Inc · Aug 26, 2026, 5:15 PM
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease DrugBenzinga · Aug 20, 2026, 1:30 PM
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037Benzinga · Aug 19, 2026, 8:07 PM
Teva Pharmaceuticals' New Drug Application For Ecopipam Gets FDA Acceptance To Treat Pediatric Patients With Tourette SyndromeBenzinga · Aug 19, 2026, 12:31 PM
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42Benzinga · Aug 12, 2026, 12:40 PM
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?The Motley Fool · Aug 3, 2026, 8:15 PM
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE ListingBenzinga · Jul 29, 2026, 5:56 PM
Teva Pharmaceutical shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance with its midpoint above estimates.Benzinga · Jul 29, 2026, 11:52 AM
Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16.400B-$16.800B to $16.500B-$16.850B vs $16.618B EstBenzinga · Jul 29, 2026, 11:20 AM
Teva Announces Replacement Of ADS Program With Direct NYSE Listing Of Ordinary Shares On One-For-One Basis; Trading Begins September 14, 2026Benzinga · Jul 29, 2026, 11:12 AM